Electrostimulation and Electromagnetic Therapy for Treating Wounds

Policy # 00030
Original Effective Date: 04/29/2002
Current Effective Date: 12/19/2018

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the “Company”), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

Transcutaneous electrical nerve stimulation as a treatment of pain and other musculoskeletal conditions is considered in medical policy 00142, Electrical Nerve Stimulation Devices.

Services Are Considered Investigational
Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers electrical stimulation for the treatment of wounds, including but not limited to low-intensity direct current (LIDC), high-voltage pulsed current (HVPC), alternating current (AC), and transcutaneous electrical nerve stimulation (TENS), to be investigational.*

Based on review of available data, the Company considers electrical stimulation performed by the patient in the home setting for the treatment of wounds to be investigational.*

Based on review of available data, the Company considers electromagnetic therapy for the treatment of wounds to be investigational.*

Background/Overview
Chronic Wounds
The normal wound healing process involves inflammatory, proliferative, and remodeling phases. When the healing process fails to progress properly, and the wound persists for more than 1 month, it may be described as a chronic wound. The types of chronic wounds most frequently addressed in studies of electrical stimulation for wound healing are (1) pressure ulcers, (2) venous ulcers, (3) arterial ulcers, and (4) diabetic ulcers.

Treatment
Conventional or standard therapy for chronic wounds involves local wound care, as well as systemic measures including débridement of necrotic tissues, wound cleansing, and dressing that promotes a moist wound environment, antibiotics to control infection, and optimizing nutritional supplementation. Avoidance of weight bearing is another important component of wound management.

Electrostimulation
Since the 1950s, investigators have used electrical stimulation as a technique to promote wound healing, based on the theory that electrical stimulation may:
Electrostimulation and Electromagnetic Therapy for Treating Wounds

Policy # 00030
Original Effective Date: 04/29/2002
Current Effective Date: 12/19/2018

- Increase adenosine 5’-triphosphate (ATP) concentration in the skin
- Increase DNA synthesis
- Attract epithelial cells and fibroblasts to wound sites
- Accelerate the recovery of damaged neural tissue
- Reduce edema
- Increase blood flow
- Inhibit pathogenesis.

Electrostimulation refers to the application of electrical current through electrodes placed directly on the skin near the wound. The types of electrostimulation and devices can be categorized into groups based on the type of current. This includes low-intensity direct current, high-voltage pulsed current, alternating current, and transcutaneous electrical nerve stimulation.

**Electromagnetic Therapy**
Electromagnetic therapy is a related but distinct form of treatment that involves the application of electromagnetic fields, rather than direct electrical current.

**FDA or Other Governmental Regulatory Approval**
U.S. Food and Drug Administration (FDA)
No electrical stimulation or electromagnetic therapy devices have received approval from the FDA, specifically for the treatment of wound healing. A number of devices have been cleared for marketing for other indications. Use of these devices for wound healing is an off-label indication.

Centers for Medicare and Medicaid Services (CMS)
National Medicare Coverage of electrical stimulation and electromagnetic stimulation is limited to chronic stage III or stage IV pressure ulcers, arterial ulcers, diabetic ulcers, and venous stasis ulcers.

Effective July, 2004, Medicare’s national coverage decision is as follows:
1. Electrical stimulation and electromagnetic therapy will not be covered as an initial treatment modality;
2. Continued treatment with electrical stimulation and electromagnetic therapy is not covered if measurable signs of healing have not been demonstrated within any 30-day period of treatment;
3. Unsupervised use of electrical stimulation or electromagnetic therapy is not covered;
4. All other uses of electrical stimulation and electromagnetic therapy for the treatment of wounds remain at the discretion of local contractors.

**Rationale/Source**
Evidence reviews assess the clinical evidence to determine whether the use of a technology improves the net health outcome. Broadly defined, health outcomes are length of life, quality of life, and ability to function—including benefits and harms. Every clinical condition has specific outcomes that are important to
Electrostimulation and Electromagnetic Therapy for Treating Wounds

Policy # 00030
Original Effective Date: 04/29/2002
Current Effective Date: 12/19/2018

patients and to managing the course of that condition. Validated outcome measures are necessary to ascertain whether a condition improves or worsens; and whether the magnitude of that change is clinically significant. The net health outcome is a balance of benefits and harms.

To assess whether the evidence is sufficient to draw conclusions about the net health outcome of a technology, 2 domains are examined: the relevance and the quality and credibility. To be relevant, studies must represent one or more intended clinical use of the technology in the intended population and compare an effective and appropriate alternative at a comparable intensity. For some conditions, the alternative will be supportive care or surveillance. The quality and credibility of the evidence depend on study design and conduct, minimizing bias and confounding that can generate incorrect findings. The randomized controlled trial (RCT) is preferred to assess efficacy; however, in some circumstances, nonrandomized studies may be adequate. RCTs are rarely large enough or long enough to capture less common adverse events and long-term effects. Other types of studies can be used for these purposes and to assess generalizability to broader clinical populations and settings of clinical practice.

A 2005 TEC Assessment concluded that there was insufficient evidence from high-quality RCTs that electrostimulation and/or electromagnetic therapy are effective as standard adjunctive treatments for wound healing. At the time, few RCTs were available, and they tended to have small sample sizes and poor methodologic quality. The following is a summary of the key literature.

ELECTROSTIMULATION

After the TEC Assessment, several RCTs and systematic reviews on electrostimulation for treating wounds have been published. Two of the systematic reviews pooled study findings.

Systematic Reviews

The 2014 systematic review by Barnes et al included RCTs evaluating the comparative effectiveness of electrostimulation for chronic ulcers of any etiology and standard treatment and/or sham stimulation. Twenty-one trials were selected; 14 used pulsed currents, 5 used alternating currents, and 2 used direct currents. Pressure ulcers were evaluated in 11 studies, venous ulcers in 3 studies, diabetic ulcers in 2 studies, arterial ulcers in 1 study, and ulcers of mixed etiology in the remaining 4 studies. Only 5 of the 21 trials were rated as “good” quality (ie, a score of 4 or 5 on the Jadad scale). Studies generally did not report the clinically important outcomes of percent completely healed or time to complete healing. Instead, they reported outcomes related to the decrease in wound size. Meta-analyses were performed on several of these secondary outcomes. A pooled analysis of 6 studies (n=201 patients) found that electrostimulation increased the mean percentage change in ulcer size by 24% to 62% compared with standard care and/or sham stimulation. The difference between groups was statistically significant (p<0.001), and heterogeneity among trials was not significant. Another pooled analysis of 6 RCTs (n=266 patients) found that electrostimulation resulted in a significantly greater reduction in mean absolute ulcer size compared with standard care and/or sham stimulation. The mean difference in size between groups was 2.42 cm² (95% confidence interval [CI], 1.66 to 3.17 cm²; p<0.001) and there was significant heterogeneity. Reviewers conducted sensitivity analyses, and the significant benefit of electrostimulation on ulcer size remained when
Electrostimulation and Electromagnetic Therapy for Treating Wounds

Policy #: 00030
Original Effective Date: 04/29/2002
Current Effective Date: 12/19/2018

Studies of pulsed current and direct current were analyzed separately. Limitations of the evidence base identified in the systematic review included few high-quality studies, variability in study designs, and lack of data on complete healing.

A 2016 systematic review by Lala et al addressed electrostimulation for treating pressure ulcers in individuals with spinal cord injury. Fifteen studies met inclusion criteria; 6 were RCTs, 6 were prospective controlled trials, 2 were retrospective controlled trials, and 4 were case series. Several studies, published by the same research group and using the same populations, might have overlapped. Reviewers used a 10-point methodologic quality score and judged the overall quality of the controlled studies to be low (mean quality score, 5.3). A pooled analysis was conducted of data from 4 RCTs that reported healing rate. Sample sizes were small: 2 of the 4 RCTs included fewer than 20 patients. In the pooled analysis, pressure ulcer healing was significantly higher with electrostimulation than sham stimulation or usual care (relative risk [RR], 1.55; 95% CI, 1.12 to 2.15). Several other pooled analyses assessed outcomes related to wound size (of less clinical interest) and data from nonrandomized studies.

A 2017 meta-analysis by Khouri et al included 29 randomized trials (total N=1510 patients; total N=1753 ulcers) of individuals treated with electrostimulation, sham stimulation, or standardized wound care. The primary finding was a highly heterogeneous overall standardized mean difference of 0.72 (95% CI, 0.48 to 1; $I^2$=78%). Modalities varied: in 18 studies, active electrostimulation was placed near the wound, and in 17 studies, electrostimulation was placed over the wound; additionally, types of waveform varied between studies (types included direct-, high-, or low-voltage current, and alternating current). Electrostimulation had the greatest efficacy when the active electrode was placed over the wound, and high-voltage pulsed current (HVPC) was used (standardized mean difference, 0.8; 95% CI, 0.38 to 1.21; $I^2$=79%). Other factors that may have affected the efficacy of electrostimulation were ulcer type, size, and duration (small, quick-healing pressure ulcers were favorable), although the association was not statistically significant ($p=0.28$). In subgroup analyses, reviewers found a greater sensitivity for wound size area than for other outcomes. Potential sources of heterogeneity were electrode polarity, ulcer etiology, and type of outcome. Reviewers noted that 52% of the studies had a high risk of bias, but concluded that the overall safety and efficacy of electrostimulation seem confirmed, given the current evidence.

**Randomized Controlled Trials**

Representative RCTs on electrostimulation for treating chronic wounds are described next (this includes the most recently published trials identified in systematic reviews).

In 2010, Houghton et al in Canada published a single-blind trial evaluating the effect of adding treatment with HVPC to a community-based standard wound care program. The trial included 34 adults with spinal cord injuries and stage II to IV pressure ulcers of at least 3 months in duration. The trial excluded potential participants who were likely to have limited healing potential (eg, those with anemia or uncontrolled diabetes). Patients in the HVPC group or their caregivers were trained to administer the treatment and instructed to apply it for 8 hours per day (eg, overnight). (A compliance analysis found that HVPC treatment was actually used for a mean of 3 hours per day.) All randomized patients completed the 3-month follow-up.
Electrostimulation and Electromagnetic Therapy for Treating Wounds

Policy #  00030
Original Effective Date:  04/29/2002
Current Effective Date:  12/19/2018

Two wounds, both in the standard care only group, were unstageable. The primary efficacy outcome (the percentage decrease in wound care surface) was significantly greater in the group receiving HVPC (n=16) than in the standard care only group (n=18) (mean decrease, 70% vs 36%, respectively; p=0.048). By 3 months, all stage II wounds had healed (one in the HVPC group, four in the standard care only group). The number of the remaining wounds (stage III, IV, or unstageable) that were at least 50% smaller at 3 months was 12 (80%) of 15 in the HVPC group and 5 (36%) of 14 in the standard care only group; this difference was statistically significant (p=0.02). There was no statistically significant difference in the number of wounds completely healed at 3 months—six in the HVPC group and five in the standard care only group.

In 2012, Franek et al in Poland evaluated high-voltage electrical stimulation for treating lower-extremity pressure ulcers in an unblinded RCT. Fifty-seven patients with stage II or III pressure ulcers were randomized to electrostimulation plus standard wound care or standard care only. The electrical stimulation intervention involved five 50-minute procedures per week until the wound was healed or until a maximum of 6 weeks. Fifty (88%) of 57 patients completed treatment. After 6 weeks, there were statistically significantly greater changes in the treatment group than in the control group on several outcomes. They included change in wound surface area (88.9% vs 44.4%, p<0.001) and change in the longest length of the wound (74.0% vs 36.1%, p<0.001), respectively. The rate of complete healing was not reported because trialists were unable to follow patients long enough for healing to occur.

In 2017, Polak et al conducted a prospective RCT in which 63 patients were randomized to cathodal or cathodal plus anodal electrostimulation by high-voltage monophasic pulsed current or sham stimulation. All patients had pressure ulcers of 0.5 cm² or greater on the pelvic girdle, and most patients (n=49 [77.78%]) were immobile; also, regardless of the regimen administered, standard wound care was given to all patients. Of patients who received high-voltage monophasic pulsed current, 23 were given daily 50-minute treatments of cathodal electrostimulation 5 times per week for 6 weeks; a comparator group (n=20) was given cathodal stimulation for 1 week, then anodal stimulation for 5 weeks. No statistically significant differences in wound-related outcomes were observed between cathodal and cathodal-anodal groups, although outcomes in both groups were significantly superior to those for the group receiving sham stimulation. Decreases in wound size area of 82.34% and 70.77% for the cathodal and cathodal-anodal groups, respectively, were significantly larger than the decrease observed in the placebo group (40.53%). Similarly, the high-voltage monophasic pulsed current groups achieved a 50% decrease in wound size area faster (1.92 weeks and 2.60 weeks) than the sham group (10.60 weeks). During the 6 weeks of treatment, 47.83% of wounds treated with cathodal stimulation closed, as did 45% of those treated with cathodal-anodal stimulation. For the sham group, none of the patients achieved full wound closure at 6 weeks. These results would suggest that the active stimulation protocols were comparable in efficacy and superior to standard wound care. Limitations of the trial were that the authors did not confirm blinding rates or follow patients to complete wound closure, so the optimal treatment time was not determined.

Section Summary: Electrostimulation
The evidence on the use of electrostimulation to treat wounds includes 2 systematic reviews, a meta-analysis, and 3 RCTs. Many studies reported short-term outcomes such as wound healing rate or decrease
Electrostimulation and Electromagnetic Therapy for Treating Wounds

Policy # 00030
Original Effective Date: 04/29/2002
Current Effective Date: 12/19/2018

in wound size; several of the trials found improvements for these outcomes. However, few studies evaluated complete healing or time to complete healing, two more clinically important outcomes. Systematic reviews were limited by the inclusion of studies with poor methodological quality and high heterogeneity.

ELECTROMAGNETIC THERAPY
Two Cochrane reviews have evaluated electromagnetic therapy for treating wounds: one addressed the treatment of pressure ulcers (last updated in 2012) and the other addressed leg ulcers (last updated in 2015). Each review identified a few RCTs (2 and 3 studies, respectively) with small sample sizes. Consequently, these reviewers were unable to conduct robust pooled analyses of study findings. Both concluded that there is insufficient evidence that electromagnetic therapy is effective for treating chronic wounds.

Khooshideh et al (2017) reported on an RCT of 72 women treated with pulsed electromagnetic field (PEMF) therapy or sham PEMF following Cesarean section. The primary outcome was a reduction of pain during recovery, which was assessed using visual analog scale (VAS) at regular intervals for 7 days following surgery. At each assessment, women treated with PEMF (n=36) reported significantly lower levels of pain than did their counterparts treated with sham (n=36). For example, 2 hours after surgery, PEMF patients had a mean VAS score of 53 compared with that of sham patients (VAS score, 63; p=0.01). Comparisons were similar between groups through the seventh day of follow-up, when the PEMF group reported a mean VAS score of 0.8 and the sham group reported a mean VAS score of 3 (p=0.01). The percentage of patients who reported severe pain (defined as VAS score, ≥75) 24 hours or less after surgery was lower in the PEMF group (36%) than in the sham group (72%; p=0.002). Secondary outcomes were wound healing and use of the pain medication available to each patient at discharge (diclofenac suppository 100 mg as needed); unlike other outcomes, wound healing was assessed 10 days after surgery, rather than 7. None of the patients in the PEMF group showed signs of wound exudate or edema, compared with 13% and 11% of sham patients who had exudate or edema, respectively (p=0.04). Patients in the PEMF group consistently used fewer suppositories to treat postoperative pain (mean, 1.7) than those treated with sham (mean, 3.7; p<0.001). Patients in both groups took an average of 3 to 4 days before they were able to resume normal activities, with no significant difference between groups (p=0.58), but listed no limitations to their study other than a change from 10 days of follow-up to 7.

Section Summary: Electromagnetic Therapy
The evidence on the use of electromagnetic therapy includes 2 systematic reviews of RCTs (one on pressure ulcers and the other on leg ulcers) and an RCT of electromagnetic treatment following Cesarean section. The reviews were limited by the inclusion of small studies and a lack of robust pooled analyses. The RCT was focused primarily on postoperative pain, with wound healing being a secondary outcome that was assessed according to a previous protocol. The evidence on the use of electromagnetic therapy to treat wounds is inadequate to support drawing conclusion about efficacy.
SUMMARY OF EVIDENCE

For individuals who have any wound type (acute or nonhealing) who receive electrostimulation, the evidence includes systematic reviews, a meta-analysis, and RCTs. Relevant outcomes are symptoms, change in health status, morbid events, quality of life, and treatment-related morbidity. Systematic reviews of RCTs on electrical stimulation have reported improvements in some outcomes, mainly intermediate outcomes such as a decrease in wound size and/or the velocity of wound healing. There are few analyses on the more important clinical outcomes of complete healing and the time to complete healing, and many of the trials are of relatively low quality. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have any wound type (acute or nonhealing) who receive electromagnetic therapy, the evidence includes 2 systematic reviews of RCTs (one on pressure ulcers and the other on leg ulcers) and an RCT of electromagnetic treatment following Cesarean section. Relevant outcomes are symptoms, change in health status, morbid events, quality of life, and treatment-related morbidity. The systematic reviews identified a few RCTs with small sample sizes that do not permit drawing definitive conclusions. The evidence is insufficient to determine the effects of the technology on health outcomes.

References
2. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Electrical stimulation or electromagnetic therapy as adjunctive treatments for chronic skin wounds. TEC Assessments 2005; Volume 20, Tab 2.
Electrostimulation and Electromagnetic Therapy for Treating Wounds

Policy # 00030
Original Effective Date: 04/29/2002
Current Effective Date: 12/19/2018


**Policy History**

<table>
<thead>
<tr>
<th>Original Effective Date</th>
<th>Current Effective Date</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>04/29/2002</td>
<td>12/19/2018</td>
<td></td>
</tr>
<tr>
<td>04/18/2002</td>
<td>Medical Policy Committee review</td>
<td></td>
</tr>
<tr>
<td>04/29/2002</td>
<td>Managed Care Advisory Council approval</td>
<td></td>
</tr>
<tr>
<td>06/24/2002</td>
<td>Format revision. No substance change to policy.</td>
<td></td>
</tr>
<tr>
<td>08/03/2004</td>
<td>Medical Director review</td>
<td></td>
</tr>
<tr>
<td>08/30/2004</td>
<td>Managed Care Advisory Council approval</td>
<td></td>
</tr>
<tr>
<td>07/14/2005</td>
<td>Medical Director review</td>
<td></td>
</tr>
<tr>
<td>07/19/2005</td>
<td>Medical Policy Committee review. Coverage changed from “eligible” to investigational.</td>
<td></td>
</tr>
<tr>
<td>08/24/2005</td>
<td>Managed Care Advisory Council approval</td>
<td></td>
</tr>
<tr>
<td>07/07/2006</td>
<td>Format revision including addition of FDA and or other governmental regulatory approval and rationale/source. Coverage eligibility unchanged.</td>
<td></td>
</tr>
<tr>
<td>05/02/2007</td>
<td>Medical Director review</td>
<td></td>
</tr>
<tr>
<td>05/07/2009</td>
<td>Medical Director review</td>
<td></td>
</tr>
<tr>
<td>06/03/2010</td>
<td>Medical Policy Committee review</td>
<td></td>
</tr>
<tr>
<td>06/16/2010</td>
<td>Medical Policy Implementation Committee approval.</td>
<td></td>
</tr>
<tr>
<td>05/05/2011</td>
<td>Medical Policy Committee review</td>
<td></td>
</tr>
<tr>
<td>05/18/2011</td>
<td>Medical Policy Implementation Committee approval. The word “Chronic” was deleted from the title.</td>
<td></td>
</tr>
<tr>
<td>05/03/2012</td>
<td>Medical Policy Committee review</td>
<td></td>
</tr>
<tr>
<td>05/16/2012</td>
<td>Medical Policy Implementation Committee approval. No change to coverage.</td>
<td></td>
</tr>
<tr>
<td>06/27/2013</td>
<td>Medical Policy Committee review and approval</td>
<td></td>
</tr>
<tr>
<td>07/17/2013</td>
<td>Medical Policy Implementation Committee review and approval. Coverage eligibility unchanged.</td>
<td></td>
</tr>
<tr>
<td>07/10/2014</td>
<td>Medical Policy Committee review and approval</td>
<td></td>
</tr>
<tr>
<td>07/16/2014</td>
<td>Medical Policy Implementation Committee review and approval. First investigational statement clarified.</td>
<td></td>
</tr>
<tr>
<td>08/03/2015</td>
<td>Coding update: ICD10 Diagnosis code section added; ICD9 Procedure code section removed.</td>
<td></td>
</tr>
<tr>
<td>10/29/2015</td>
<td>Medical Policy Committee review and approval</td>
<td></td>
</tr>
<tr>
<td>11/16/2015</td>
<td>Medical Policy Implementation Committee review and approval. Coverage eligibility unchanged.</td>
<td></td>
</tr>
</tbody>
</table>

©2018 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Electrostimulation and Electromagnetic Therapy for Treating Wounds

Policy # 00030
Original Effective Date: 04/29/2002
Current Effective Date: 12/19/2018

12/01/2016 Medical Policy Committee review and approval
12/21/2016 Medical Policy Implementation Committee review and approval. Coverage eligibility unchanged.
01/01/2017 Coding update: Removing ICD-9 Diagnosis Codes
12/07/2017 Medical Policy Committee review and approval
12/20/2017 Medical Policy Implementation Committee review and approval. Coverage eligibility unchanged.
12/06/2018 Medical Policy Committee review and approval
12/19/2018 Medical Policy Implementation Committee review and approval. Coverage eligibility unchanged.
01/01/2019 Coding update

Next Scheduled Review Date: 12/2019

Coding
The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®), copyright 2017 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

<table>
<thead>
<tr>
<th>Code Type</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>Code deleted eff 1/1/19: 64550</td>
</tr>
<tr>
<td>HCPCS</td>
<td>C1816, C1883, E0761, E0769, G0281, G0282, G0295, G0329</td>
</tr>
<tr>
<td>ICD-10 Diagnosis</td>
<td>All related diagnoses</td>
</tr>
</tbody>
</table>

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. FDA and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or

B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:

©2018 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Electrostimulation and Electromagnetic Therapy for Treating Wounds

Policy # 00030
Original Effective Date: 04/29/2002
Current Effective Date: 12/19/2018

1. Consultation with the Blue Cross and Blue Shield Association TEC or other nonaffiliated technology evaluation center(s);
2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
3. Reference to federal regulations.

† Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.